TY - JOUR
T1 - Lutetium-177 DOTATATE
T2 - A Practical Review
AU - Jia, Angela Y.
AU - Kashani, Rojano
AU - Zaorsky, Nicholas G.
AU - Spratt, Daniel E.
AU - Kiess, Ana P.
AU - Michalski, Jeff M.
AU - Zoberi, Jacqueline E.
AU - Kim, Hyun
AU - Baumann, Brian C.
N1 - Funding Information:
Disclosures: Dr Kiess reports grants from Bayer, Novartis, and Merck. Dr Spratt reports honoraria for lectures and presentations from AstraZeneca, Bayer, Blue Earth, Boston Scientific, Novartis, Janssen, Gammatile, and Varian Medical Systems. Dr Baumann reports consulting fees from Boston Scientific and Varian Medical Systems, participation in data safety monitoring board from Galera Therapeutics and Regeneron/Sanofi, and honoraria from Mevion - all of which are outside the submitted work, and is a board member of the National Association of Proton Therapy. Dr Zaorsky is supported by the National Institutes of Health grant LRP 1 L30 CA231572-01 and is supported by the American Cancer Society – Tri State CEOs Against Cancer Clinician Scientist Development Grant, CSDG-20-013-01-CCE. Dr Zaorsky received remuneration from Springer Nature for his textbook, Absolute Clinical Radiation Oncology Review. All other authors have no disclosures to declare.
Funding Information:
Sources of support: This work had no specific funding. Disclosures: Dr Kiess reports grants from Bayer, Novartis, and Merck. Dr Spratt reports honoraria for lectures and presentations from AstraZeneca, Bayer, Blue Earth, Boston Scientific, Novartis, Janssen, Gammatile, and Varian Medical Systems. Dr Baumann reports consulting fees from Boston Scientific and Varian Medical Systems, participation in data safety monitoring board from Galera Therapeutics and Regeneron/Sanofi, and honoraria from Mevion - all of which are outside the submitted work, and is a board member of the National Association of Proton Therapy. Dr Zaorsky is supported by the National Institutes of Health grant LRP 1 L30 CA231572-01 and is supported by the American Cancer Society – Tri State CEOs Against Cancer Clinician Scientist Development Grant, CSDG-20-013-01-CCE. Dr Zaorsky received remuneration from Springer Nature for his textbook, Absolute Clinical Radiation Oncology Review. All other authors have no disclosures to declare.
Publisher Copyright:
© 2022 American Society for Radiation Oncology
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.
AB - Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.
UR - http://www.scopus.com/inward/record.url?scp=85132455738&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2022.02.002
DO - 10.1016/j.prro.2022.02.002
M3 - Article
C2 - 35717045
AN - SCOPUS:85132455738
SN - 1879-8500
VL - 12
SP - 305
EP - 311
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 4
ER -